Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05947643 · ClinicalTrials.gov registry record · Phase 2

Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)

A Phase 2 study of COVID-19, sponsored by Washington University School of Medicine.

Completed
Registry status
Phase 2
Development phase
77
Enrollment target
1
Study location

NCT05947643 is a Phase 2 study of COVID-19 that has completed, run by Washington University School of Medicine. The registered enrollment target is 77 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05947643, a Phase 2 study of COVID-19, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
Phase 2
Development phase
77 participants
Enrollment target
1
Study location

Study Summary

The purpose of this Phase II trial is to test the effectiveness of intranasal theophylline irrigations for the treatment of COVID-19 related smell dysfunction. The investigators will compare the effect of theophylline nasal rinses versus placebo nasal rinses on smell symptoms. Participants will be asked to rinse their nose with a medication or placebo capsule dissolved in saltwater twice daily for 12 weeks and fill out surveys about smell before, during, and at the end of treatment. This study will also be used to describe adverse effects related to intranasal theophylline irrigation.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG theophylline

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 77 participants
Start Date 2022-11-22
Est. Completion 2025-08-04
Phase Phase 2

What the Registry Record Tells You About NCT05947643

The ClinicalTrials.gov registry entry for NCT05947643 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05947643 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT05947643 about?

NCT05947643 is a clinical study titled "Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)". The purpose of this Phase II trial is to test the effectiveness of intranasal theophylline irrigations for the treatment of COVID-19 related smell dysfunction. The investigators will compare the effect of theophylline nasal rinses versus placebo nasal rinses on smell symptoms. Participants will be a...

What is the current status of trial NCT05947643?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2022-11-22. Estimated completion is 2025-08-04.

What conditions does trial NCT05947643 study?

This clinical trial studies the following conditions: COVID-19.

What interventions are being tested in trial NCT05947643?

The interventions under investigation include: Placebo (DRUG), theophylline (DRUG).

Who is sponsoring clinical trial NCT05947643?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05947643 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.